Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 60/952,547, filed Jul 27, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,974,791 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS In force · High confidence UsedRemaining | Armagen, Inc. | In force | High confidence | ||
| US 9,567,400 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS In force · High confidence | JCR Pharmaceuticals Co., Ltd. | In force | High confidence | ||
| US 10,202,467 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS In force · Medium confidence | JCR Pharmaceuticals Co., Ltd. | In force | Medium confidence | ||
| US 11,512,145 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS In force · High confidence | Armagen, Inc. | In force | High confidence | ||
| Application 18/048,000 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS Pending Not granted | Armagen, Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Armagen, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.